Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment Targets for Chronic Hypertension in Pregnancy
NCT00194974Phase 2Withdrawn
- Sponsor
- Weill Cornell Medicine
- Start
- Jul 2004
- Primary completion
- Mar 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of methyldopa, labetalol, nifedipine, hydralazine and clonidine in hypertension (HTN) and preeclampsia (2 arms), sponsored by Weill Cornell Medicine. Primary endpoint: Achievement of target blood pressure at 38 weeks. Planned start Jul 2004; status: withdrawn.
02
Drugs
methyldopalabetalolnifedipinehydralazineclonidine
03
Conditions
hypertension (HTN)preeclampsia
Beyond the preview
Go deeper on NCT00194974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00194974.